Genes that are up- or down-regulated during differentiation of human embryonic stem cells

• US 20030224411A1
• Filed: 03/13/2003
• Published: 12/04/2003
• Est. Priority Date: 03/13/2003
• Status: Abandoned Application

• Current Assignee: Asterias Biotherapeutics Incorporated (Lineage Cell Therapeutics, Inc.)
• Original Assignee: Asterias Biotherapeutics Incorporated (Lineage Cell Therapeutics, Inc.)
• Inventors: Gold, Joseph D., Mandalam, Ramkumar, Brandenberger, Ralph, Shelton, Dawne, Irving, John M., Stanton, Lawrence W., Mok, Michael
• Application Number:
  US10/388,578
• Publication Number:
  US 20030224411A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/68 involving nucleic acids
• CPC Class Codes: C12Q 1/6876 Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

Genes that are up- or down-regulated during differentiation provide important leverage by which to characterize and manipulate early-stage pluripotent stem cells. Over 35,000 unique transcripts have been amplified and sequenced from undifferentiated human embryonic stem cells, and three types of differentiated progeny. Statistical analysis of the assembled transcripts identified genes that alter expression levels as differentiation proceeds. The expression profile provides a marker system that has been used to identify particular culture components for maintaining the undifferentiated phenotype. The gene products can also be used to promote differentiation; to assess other relatively undifferentiated cells (such as cancer cells); to control gene expression; or to separate cells having desirable characteristics. Manipulation of particular genes can be used to forestall or focus the differentiation process, en route to producing a specialized homogenous cell population suitable for human therapy.

Claims

1. A method for assessing a culture of undifferentiated primate pluripotent stem (pPS) cells or their progeny, comprising detecting or measuring expression of two or more of the markers in any of Tables 5 to 9, other than hTERT or Oct 3/4.

2. The method of claim 1, comprising measuring expression of two or more of the markers in Tables 2, 7, and 9(C), and correlating the expression measured with the presence of undifferentiated embryonic stem (ES) cells in the culture.

3. The method of claim 1, comprising measuring expression of two or more of the markers in Tables 3 and 8, and correlating the expression measured with the presence of differentiated cells in the culture.

4. The method of claim 1, comprising detecting or measuring expression of one or more of the following markers:

bone marrow stromal antigen;

Podocalyxin-like;

Rat GPC/glypican-2 (cerebroglycan);

Potassium channel subfamily k member 5 (TASK-2);

Notch 1 protein;

Teratocarcinoma-derived growth factor 1 (Cripto);

Nel 1 like/NELL2 (Nel-like protein

     2);

Gastrin releasing peptide receptor;

Bone morphogenetic protein;

ABCG2- ABC transporter;

Solute carrier family 6, member 8 (SLC6A8);

hTERT;

Oct 3/4 Octamer-binding transcription factor 3a (Oct-3a) (Oct-4);

Left-right determination factor b (LEFT);

Secreted phosphoprotein 1 (osteopontin);

Gamma-aminobutyric acid (GABA) A receptor, beta 3;

Roundabout, axon guidance receptor, homologue 1 (ROBO1);

Glucagon receptor;

Leucine-rich ppr-motif hum 130 kDa hum130leu 130 kd leu;

Thy-1 co-transcribed;

Solute carrier family 21;

LY6H lymphocyte antigen 6 complex locus H;

Plexin (PLXNB3);

Armadillo repeat protein deleted in velo-cardio-facial syndrome; and

Ephrin type-a receptor 1 (EPHA1).

5. The method of claim 1, comprising detecting or measuring expression of three or more of said markers.

6. The method of claim 1 further comprising detecting or measuring expression of hTERT and/or Oct 3/4.

11. The method of claim 1, wherein expression of the marker(s) is detected or measured at the mRNA level by PCR amplification.

12. The method of claim 1, wherein expression of the marker(s) is detected or measured at the protein or enzyme product level by antibody assay.

13. The method of claim 1, comprising quantifying the proportion of undifferentiated pPS cells or differentiated cells in the culture from said marker expression.

14. The method of claim 1, comprising assessing the ability of a culture system or component thereof to maintain pPS cells in an undifferentiated state from said marker expression.

15. The method of claim 14, comprising assessing the ability of a soluble factor to maintain pPS cells in an undifferentiated state from said marker expression.

16. The method of claim 14, comprising assessing the ability of a culture medium to maintain pPS cells in an undifferentiated state from said marker expression.

17. The method of claim 14, comprising assessing the ability of a preparation of feeder cells to maintain pPS cells in an undifferentiated state from said marker expression.

18. The method of claim 1, comprising assessing the ability of a culture system or component thereof to cause differentiation of pPS cells into a culture of lineage-restricted precursor cells and/or terminally differentiated cells.

19. The method of claim 1, comprising assessing the suitability of a pPS cell culture for preparing cells for human administration.

41. A method for causing pPS cells to proliferate without differentiation, comprising culturing them in a culture system assessed according to the method of claim 6.

45. A kit for assessing a culture of pPS cells according to claim 1, comprising polynucleotide probes and/or primers for specifically amplifying a transcript for two or more markers in any of Tables 5 to 9, accompanied by written instructions for assessing the pPS cells or their progeny according to the expression of said markers measured using the probes or primers in the kit.

46. A kit for assessing a culture of pPS cells according to claim 1, comprising antibodies specific for each gene product of two or more markers in any of Tables 5 to 9, accompanied by written instructions for assessing the pPS cells or their progeny according to the expression of said markers measured using the antibodies in the kit.

47. The method of claim 1, wherein the pPS cells are obtained from a human blastocyst, or are the progeny of such cells.

48. The method of claim 1, wherein the pPS cells are human embryonic stem cells.

7. A method for assessing a culture of undifferentiated primate pluripotent stem (pPS) cells or their progeny, comprising detecting or measuring:

a marker from the following list;

Cripto, gastrin-releasing peptide (GRP) receptor, and podocalyxin-like protein; and

either hTERT and/or Oct 3/4, or a second marker from the list.

8. The method of claim 7, comprising detecting or measuring at least two markers from the list.

9. The method of claim 7, comprising detecting or measuring at least two markers from the list, and detecting or measuring hTERT and/or Oct 3/4.

10. The method of claim 7, comprising detecting or measuring Cripto, gastrin-releasing peptide (GRP) receptor podocalyxin-like protein, hTERT, and Oct 3/4.

20. The method of claim 7, wherein the level of the marker is determined to be at least 100-fold higher than the level of the marker in BJ fibroblasts.

21. A method for assessing the growth characteristics of a cell population, comprising detecting or measuring expression of two or more of the markers in any of Tables 5 to 9, at least one of which is neither hTERT nor Oct 3/4.

22. The method of claim 21, comprising detecting or measuring:

a marker from the following list;

Cripto, gastrin-releasing peptide (GRP) receptor, and podocalyxin-like protein; and

either hTERT and/or Oct 3/4, or a second marker from the list.

23. The method of claim 21, wherein the cell population has been obtained by culturing cells from a human blastocyst.

24. The method of claim 23, comprising determining whether the cell population is pluripotent from said marker expression.

25. The method of claim 21, wherein the cell population has been obtained from a human patient suspected of having a clinical condition related to abnormal cell growth.

26. The method of claim 25, comprising assessing whether the patient has a malignancy from said marker expression.

27. A method for maintaining pPS cells in a pluripotent state, comprising causing them to express one of the following markers at a higher level:

Forkhead box O1A (FOXO1A);

Zic family member 3 (ZIC3);

Hypothetical protein FLJ20582;

Forkhead box H1 (FOXH1);

Zinc finger protein, Hsal2;

KRAB-zinc finger protein SZF1-1;

or Zinc finger protein of cerebellum ZIC2;

or

any other marker listed in Table 5 with the symbol “

{circle over (x)}”

.

28. The method of claim 27, wherein the cells are caused to express the marker by genetically altering it with a gene that encodes the marker.

29. A method for causing pPS cells to differentiate into a particular tissue type, comprising causing them to express one of the following markers at a lower level:

Forkhead box O1A (FOX01A);

Zic family member 3 (ZIC3);

Hypothetical protein FLJ20582;

Forkhead box H1 (FOXH1);

Zinc finger protein, Hsal2;

KRAB-zinc finger protein SZF1-1;

or Zinc finger protein of cerebellum ZIC2;

or

any other maker listed in Table 5 with the symbol “

{circle over (x)}”

;

or by causing them to express one of the markers listed in Table 6 with the symbol “

{circle over (x)}”

at a higher level.

30. The method of claim 29, wherein the cells are caused to express the marker by genetically altering it with a gene that encodes the marker.

31. A method for maintaining pPS cells in a pluripotent state, comprising culturing pPS cells or their progeny in the presence of a normally secreted protein that is encoded by a gene listed in Table 2, 5, 7, or 9.

32. A method for causing pPS cells to differentiate, comprising culturing pPS cells or their progeny in the presence of a normally secreted protein that is encoded by a gene listed in Table 3, 6, or 8.

33. A method for causing an encoding sequence to be preferentially expressed in undifferentiated pPS cells, comprising genetically altering pPS cells with the encoding sequence under control of a promoter for one of the markers listed in Table 2, 5, or 7.

34. The method of claim 33, further comprising selecting undifferentiated cells, wherein the encoding sequence is a reporter gene (such as a gene that causes the cells to emit fluorescence), or a positive selection marker (such as a drug resistance gene).

35. The method of claim 33, further comprising depleting undifferentiated cells from a population of differentiated cells, wherein the encoding sequence is a negative selection marker (such as a gene that activates apoptosis or converts a prodrug into a compound that is toxic to the cell).

36. A method for causing an encoding sequence to be preferentially expressed in differentiated cells, comprising genetically altering the pPS cells with the encoding sequence under control of a promoter for one of the markers listed in Table 3, 6, or 8.

37. The method of claim 36, further comprising selecting differentiated cells, wherein the encoding sequence is a reporter gene (such as a gene that causes the cells to emit fluorescence), or a positive selection marker (such as a drug resistance gene).

38. The method of claim 36, further comprising depleting differentiated cells from a population of undifferentiated cells, wherein the encoding sequence is a negative selection marker (such as a gene that activates apoptosis or converts a prodrug into a compound that is lethal to the cell).

39. A method for sorting differentiated cells from less differentiated cells, comprising separating cells expressing a surface marker in any of Tables 5 to 9 from cells not expressing the marker.

40. The method of claim 39, wherein the cells are sorted using an antibody or lectin that binds the marker or product thereof on the cell surface.

42. A method for causing pPS cells to proliferate without differentiation, comprising culturing them with mesenchymal stem cells.

43. A method for identifying genes that are up- or down-regulated during differentiation of pPS cells, comprising:

a) sequencing transcripts in an expression library from undifferentiated pPS cells;

b) sequencing transcripts in one or more expression libraries from one or more cell types that have differentiated from the same line of pPS cells;

c) determining the frequency of transcripts from each gene sequenced in each of the libraries; and

d) identifying the gene as being up- or down-regulated during differentiation of the pPS cells if the frequency of transcripts in the library from the undifferentiated pPS cells is statistically different from the frequency of transcripts in one or more libraries from the differentiated cell types.

44. The method of claim 43, further comprising assessing a culture of pPS cells depending on the expression level in the culture of a marker identified in step d).